WO2008001311A2 - Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide - Google Patents

Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide Download PDF

Info

Publication number
WO2008001311A2
WO2008001311A2 PCT/IB2007/052479 IB2007052479W WO2008001311A2 WO 2008001311 A2 WO2008001311 A2 WO 2008001311A2 IB 2007052479 W IB2007052479 W IB 2007052479W WO 2008001311 A2 WO2008001311 A2 WO 2008001311A2
Authority
WO
WIPO (PCT)
Prior art keywords
atenolol
isosorbide mononitrate
poly
composition according
pharmaceutical composition
Prior art date
Application number
PCT/IB2007/052479
Other languages
English (en)
Other versions
WO2008001311A3 (fr
Inventor
Rajan K. Verma
Narayanan Badri Viswanathan
Ashok Rampal
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2008001311A2 publication Critical patent/WO2008001311A2/fr
Publication of WO2008001311A3 publication Critical patent/WO2008001311A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate and process for the preparation thereof.
  • the compositions are useful for the treatment of patients with angina.
  • Angina pectoris is typically described as a substernal chest discomfort perceived as tightness, heaviness, or pressure, or a burning sensation.
  • Angina pectoris results when myocardial oxygen demand is increased to levels that cannot be met through increased coronary blood flow, usually due to obstruction or spasm of the coronary arteries (ihe heart's blood vessels).
  • the aims of treatment of angina are to minimize or abolish symptoms; and to improve prognosis by preventing myocardial infarction and death.
  • beta blocker should be the first line, unless there are contraindications; a selective beta blocker, such as atenolol is preferred; long-acting nitrates or calcium antagonists in combination with beta-blockers are recommended when initial treatment with beta-blockers is not successful; and special efforts should be made to ensure compliance with the prescribed therapy.
  • Atenolol is chemically described as 4-[2-hydroxy-3- [(1- methyiethyl) amino] propoxy] benzeneacetamide). A significant beta-blocking effect of atenolol is apparent within one hour following oral administration of a single dose.
  • Isosorbide mononitrates is chemically described as 8-nitrooxy-2, 6- dioxabicyclo [3.3.0] octan-4-oi, and is alone used as vasodilator that is able to reduce myocardial oxygen demands while maintaining or increasing coronary artery flow.
  • the combination of isosorbide mononitrate with atenolol provides a synergistic effect, as compared to the monotherapy. While atenolol acts by reducing myocardial oxygen demand through reduction of the (heart rate) X (blood pressure) product, isosorbide mononitrate has beneficial effects on both demand (reduction in preload and afterload) and supply (coronary perfusion).
  • ISMN Retard In order to prevent the development of nitrate tolerance, ISMN Retard is designed to act for only about 16 hours so as to provide the 'nitrate free interval' that restores responsiveness to the drug. However, during this period, rebound of symptoms may occur in those on ISMN Retard therapy alone. This can be obviated by the concomitant use of another class of anti-anginal drug. Atenolol, used in combination wilh ISMN Retard would continue to provide anti-anginal protection during the 'nitrate free interval' (that is deliberately built into the design of ISMN Retard).
  • the tendency of ISMN to cause reflex tachycardia is countered by the bradycardic action of atenolol.
  • both atenolol and ISMN Retard are suitable for patients with or without concomitant hypertension.
  • the dosage of atenolol in angina is 50mg once daily, which can be increased to lOOmg once daily. Some patients require 200rag once daily for effective control,
  • the dosage of ISMN Retard in angina is 60mg to 240mg once daily.
  • Atenolol and isosorbide mononitrate are commercially available in the form of tablets of the individual drugs or in combination with other drugs.
  • the tablets may be in the form of either immediate release (IR) formulations or controlled release (CR) formulations.
  • IR immediate release
  • CR controlled release
  • U.S. Patent Application No. 2003185887 discloses a controlled release formulation of beta blockers, the formulation is in the form of a capsule containing pellets comprising a beta- adrenergic blocking agents.
  • U.S. Patent No 6,641,839 discloses a controlled release formulation of isosorbide mononitrate in which the sugar spheres are coated with isosorbide mononitrate and a diffusion control membrane surrounds the core.
  • U.S. Patent No 5,334,393 discloses a sustained-release tablet of isosorbide mononitrate in which isosorbide is dispersed in a hydrophilic matrix.
  • U.S. Patent No 5,869,094 discloses a solid form of oral administration of isosorbide 5-mononitrate with a controlled, pH-independent release of the active substance in the gastrointestinal tract and is constituted by a pellet coated with a depot layer and a release prolonging lacquer layer. The lacquer layer contains ethyl cellulose and polymethacrylate.
  • European Patent No. 1088554 discloses controlled release formulation of isosorbide in combination with acetylsa ⁇ cylic acid. US Patent Application No.
  • 2002077348 discloses a single dosage formulation having a beta-adrenergic blocker and a cholesterol lowering agent that is a statin.
  • U.S. Patent No. 5,032,591 discloses a combination of beta blocker with a potassium channel activator antihypertensive agent.
  • ISMN Isosorbide Mononitrate
  • the present invention relates Io pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate, in which atenolol is present in the immediate release form and isosorbide mononitrate is present in the extended release form.
  • the composition has additive antianginal effect, has increased efficacy and improved patient compliance.
  • a pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate, the composition providing extended release of isosorbide mononitrate and immediate release of atenolol.
  • compositions containing fixed dose combination of atenolol with isosorbide mononitrate wherein the composition comprises: a) an extended release component comprising isosorbide mononitrate, one or more rate controlling agents, and optionally one or more pharmaceutically acceptable excipients, and, b) an immediate release component comprising atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients.
  • compositions containing fixed dose combination of atenolol with isosorbide mononitrate wherein the composition comprises: a) an extended release tablet comprising isosorbide mononitrate, one or more rate controlling agents, and optionally one or more pharmaceutically acceptable excipients, and b) an immediate release atenolol coating surrounding the tablet and comprising atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients.
  • compositions containing fixed dose combination of atenolol with isosorbide mononitrate wherein the composition comprises: a) a core comprising isosorbide mononitrate, b) a controlled release coating surrounding the core, and c) an immediate release atenolol coaling above the controlled release coating and comprising atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients.
  • a process for preparing a pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprising the steps of: a) granulating isosorbide mononitrate, one or more rate controlling agents and optionally, one or more pharmaceutically acceptable excipients, optionally followed by drying to obtain extended release granules, b) granulating atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients, optionally followed by drying to obtain immediate release granules, and, c) compressing the extended release granules obtained in step (a) and the immediate release granules obtained in step (b) to form bilayered tablet.
  • a process for preparing pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprising the steps of: a) dispersing isosorbide mononitrate in one or more of molten hydrophobic substance followed by solidifying and, optionally mixing with one or more hydrophilic polymers to obtain extended release granules, b) granulating atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients, followed by drying to obtain immediate release granules, and, c) compressing the extended release granules obtained in step (a) and the immediate release granules obtained in step (b) to form bilayered tablet.
  • the present invention relates to a pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate for the treatment of angina, in which isosorbide mononitrate is present in an extended release form and atenolol is present in an immediate release form.
  • the 'fixed dose combination' of the present invention comprises atenolol in an amount ranging from 25 to lOOmg; and isosorbide mononitrate in art amount ranging from 30 to 120mg.
  • the fixed dose combination comprises atenolol in an amount of 50mg and isosorbide mononitrate in an amount of 30 and 60mg.
  • isosorbide mononitrate as used herein and in the appended claims may include isosorbide-2-mononitrate or isosorbide-5-mononitrate.
  • atenolol as used herein and in the appended claims refers to atenolol, single enatiomers, pharmaceutically acceptable salts or mixtures thereof.
  • compositions of the present invention includes an extended release component and an immediate release component.
  • the composition may be in the form of tablets or capsules.
  • the tablets may be uncoated tablets, coaled tablets or bilayered tablets.
  • the immediate release/ extended release components may be in the form of pellets, beads, granules, capsules or tablets.
  • extended release means that the release of the drug is at a rate such that blood (e.g., plasma) levels are maintained within the therapeutic range but beiow toxic levels over a period of time greater than 6 hours, more preferably for about 12 to about 16 hours.
  • immediate release means that the entire drug may be released within two hours or less following administration.
  • the pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprises: a) an extended release component comprising isosorbide mononitrate, one or more rate controlling agents, and optionally one or more pharmaceutically acceptable excipients, and, b) an immediate release component comprising atenolol, optionally one or more disintegranis and optionally one or more pharmaceutically acceptable excipients.
  • the rate controlling agent may be selected from one or more of hydrophilic polymers, hydrophobic polymers and hydrophobic substance.
  • the hydrophilic polymers may be selected from one or more of cellulose derivatives such as hydroxypropyl methyicelluiose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose or sodium carboxymethyl cellulose; gums such as xanthan gum, karaya gum, locust bean gum, alginic acid or sodium alginate; and vinyl alcohol or v ⁇ nylpyrroiidone based polymers such as polyvinyl alcohol, or polyvinylpyrrolidone; polyethylene oxides.
  • hydroxypropyl methyicelluiose HPMC
  • hydroxypropylcellulose carboxymethylcelluiose
  • Suitable hydrophobic polymers may be selected from one or more of ethylcelJuiose, cellulose acetate, cellulose propionate, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly (methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate ⁇ , poly ⁇ exyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), polyphenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), poly(ethylene), poly(ethylene), polypropylene), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl isobutyl ether), polyvinyl acetate), poly(vinyl chloride
  • the hydrophobic substance may be selected from one or more of fatty acids, fatty alcohols, glyceryl esters of tally acids, mineral and vegetable oils and waxes.
  • hydrophobic substances include beeswax, carnauba wax, paraffin wax, stearic acid, stearyl alcohol and glyceryl behenate.
  • rate-controlling agents can be used alone or in combination.
  • the rate controlling agent can be used in a concentration of 2% to 60% depending on the agent used,
  • Suitable disintegrants may be selected from one or more of sodium starch glycolate, croscarmellose sodium, crospov ⁇ done, com starch, low substituted hydroxy propyl cellulose, starch and mixtures thereof.
  • the 'pharmaceutically acceptable excipients' may include diluent, binder, lubricant, glidant and coloring agent.
  • the diluent may be selected from microcrystalline cellulose, lactose, mannitol, dicalcium phosphate, starch or mixtures thereof.
  • the binder may be selected from starch, polyvinylpyrrolidone, natural or synthetic gum, cellulosic polymers or mixtures thereof.
  • Lubricant and glidant may be selected from talc, colloidal silicon dioxide, magnesium slearate or mixtures thereof. Examples of coloring agents include any FDA approved colors for oral use.
  • the pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate is in the form of a bilayered tablet.
  • the bilayered tablet includes two separate drug layers of atenolol and isosorbide mononitrate, and has only one surface in contact with each other, i.e., the bilayered tablet may comprise one extended release layer comprising isosorbide mononitrate and one immediate release layer comprising atenolol.
  • the pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprises: a) an extended release isosorbide mononitrate tablet, and b) an immediate release atenolol coating surrounding the tablet.
  • the immediate release atenolol coating surrounding the tablet releases the atenolol substantially immediately upon ingestion.
  • the extended release isosorbide mononitrate may be in the form of multiparticulate system, i. e. granules, beads or pellets, which may be coated with the immediate release atenolol coating.
  • the immediate release atenolol coating may include water-soluble polymers such as polyvinyl pyrrolidine, hydroxypropyl cellulose, polyvinyl alcohol or hydroxypropyl methylcellulose. Further, conventional pharmaceutically acceptable excipients like diluents, plasticizers and lubricants may also be incorporated into this coating.
  • the pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprises a) a core comprising isosorbide mononitrate, b) a controlled release coating surrounding the core, and c) an immediate release atenolol coating above the controlled release coaling.
  • the core may be in the form of pellets, beads, granules, or tablets, comprising isosorbide mononitrate.
  • the core is in the form of a bead wherein, an inert carrier is layered with isosorbide mononitrate.
  • the inert carrier comprises one or more of starch, microcrystalline cellulose or nonpareil sugar seeds.
  • the controlled release coating comprises one or more rate controlling agents.
  • the coating may optionally also include water soluble polymers, plasticizers and lubricants.
  • compositions of the present invention may be prepared by conventional processes known to person skilled in the art,
  • the tablets may be prepared by wet granulation, dry granulation or direct compression process.
  • a process for preparing a pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprising the steps of: a) granulating isosorbide mononitrate, one or more rate controlling agents and optionally, one or more pharmaceutically acceptable excipients, optionally followed by drying to obtain extended release granules, b) granulating atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients, optionally followed by drying to obtain immediate release granules, and, c) compressing the extended release granules obtained in step (a) and the immediate release granules obtained in step (b) to form bilayered tablet.
  • a process for preparing pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate comprising the steps of; a) dispersing isosorbide mononitrate in one or more molten hydrophobic substance followed by solidifying and, optionally mixing with one or more hydrophilic polymers to obtain extended release granules, b) granulating atenolol, optionally one or more disintegrants and optionally one or more pharmaceutically acceptable excipients, optionally followed by drying to obtain immediate release granules, and, c) compressing the extended release granules obtained in step (a) and the immediate release granules obtained in step (b) to form bilayered tablet.
  • Isosorbide Mononitrate 80% diluted, Povidone (part 1), Lactose monohydrat ⁇ , Microcrystalline Cellulose, and Hypromeilose were sifted through # 22 BSS and lake of
  • step 2 The mixture of step 1 was granulated with Povidone (part 2) solution in a mixture of Isopropyi Alcohol and Purified Water to obtain a wet mass. 3. The wet mass obtained in step 2 was dried to obtain the dried granules; the dried granules btained were then lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearale to obtain a blend.
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycolate (Part 1) were sifted tlirough # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution in Purified Water to obtain a wet mass.
  • step 3 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2). 4. The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • Dissolution Profile The dissolution for isosorbide mononitrate was carried out in USP Apparatus Type 2 at a speed of 50 rpm.
  • the medium was 900 ml 0.1 N hydrochloric acid.
  • the dissolution for atenolol was carried out in USP Apparatus Type I at a speed of 100 rpm.
  • the medium was 900 ml 0.1 N hydrochloric acid.
  • Isosorbide Mononitrate 80% diluted, Povidone ⁇ part 1), Microcrystalline Cellulose, and Hypromellose were sifted through # 22 BSS and lake of Erythrosine was sifted through # iOO BSS and mixed to obtain a mixture.
  • step 2 The mixture of step 1 was granulated with Povidone (part 2) solution in a mixture of ⁇ sopropyl Alcohol and Purified Water to obtain a wet mass.
  • step 3 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules obtained were milled and lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Slearate to obtain a blend.
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycolate (Part 1) were sifted through # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution (in Purified Water) to obtain a wet mass.
  • step 2 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 2 Granulate mix of step 1 with Povidone (part 2) solution (in a mixture of Isopropyl Alcohol and Purified Water) to obtain wet mass.
  • step 3 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules obtained were milled and lubricated with Colloidal Anhydrous Silica, Talc, and
  • Atenolol, Microcrystailine Cellulose, and Sodium Starch Glycolate Part 1 were sifted through # 22 BSS and mixed to obtain a mixture 2.
  • step 2 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate ( Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • Isosorbide Mononitrate 80% diluted, Povidone (part 1), Glyceryl behenate, Microcrystalline Cellulose, and Hypromellose were sifted through # 22 BSS and lake of Erythrosine was sifted through # 100 BSS and were mixed to obtain a mixture.
  • step 2 The mixture obtained in step 1 was granulated with Povidone (part 2) solution in a mixture of Isopropyl Alcohol and Purified Water to obtain a wet mass.
  • step 3 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules obtained were lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.
  • Atenolol, MicrocrystaHine Cellulose, and Sodium Starch Glycolate Part 1 were sifted through # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution (in Purified Water) to obtain a wet mass,
  • step 2 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obiained in (B).
  • Isosorbide Mononitrate 80% diluted, Povidone (part 1), ethylcellulose (Ethocel 100 FP), Microcrystalline Cellulose, and Hyprornell ⁇ se were sifted through # 22 BSS and lake of Erythrosine was sifted through # 100 BSS and mixed to obtain a mixture.
  • step 2 The mixture obtained in step 1 was granulated with Povidone (part 2) solution in a mixture of Isopropyl Alcohol and Purified Water to obtain wet mass.
  • step 3 The wet mass of step 2 was dried to obtain dried granules, the dried granules obtained were milled and lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium S tearate to obtain a blend .
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glyco ⁇ ate (Part 1 ) were sifted through # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution in Purified Water to obtain a wet mass.
  • step 2 The wet mass obtained in step 2 was dried Io obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 2 The mixture obtained in step 1 was granulated with Povidone (part 2) solution in a mixture of Isopropyl Alcohol and Purified Water to obtain wet mass.
  • step 3 The wet mass obtained in step 2 was milled and dried to obtain dried granules, the dried granules obtained were mixed with ethylceilulose (Ethocel 100 FP). 4. The granules obtained in step 3 were lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycolate (Part 1) were sifted through # 22 BSS and mixed to obtain a mixture 2.
  • the mixture obtained in step 1 was granulated with Povidone solution in Purified
  • step 2 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 2 Granulate mixture obtained in step 1 with Povidone (part. 2) solution in a mixture of Isopropyl Alcohol and Purified Water to obtain a wet mass.
  • step 2 Wet mass obtained after step 2 was dried, milled and then lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.
  • step 3 Wet mass obtained after step 2 was dried, milled and then lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.
  • step 3 Wet mass obtained after step 2 was dried, milled and then lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycolate (Part. 1 ) were sifted through # 22 BSS to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution (in Purified Water) to obtain a wet mass. 3. The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • Microcrystalline Cellulose, and Hypromellose were sifted through # 22 BSS and lake of Erythrosine through was sifled through # 100 BSS to obtain a mixture.
  • step 3 The mixture obtained in step 2 was mixed with granules of step 1 to obtain a blend.
  • step 3 The blend obtained in step 3 was lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate.
  • Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycolate (Part 1 ) were sifted through # 22 BSS and mixed to obtain a mixture.
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution in Purified Water to obtain a wet mass. 3. The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bi layer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 1 Ca ⁇ iauba wax was melted and to this stearic acid and Isosorbide Mononitrate 80% diluted were added while siirring. 2. All the melt of step 1 was solidified and milled, and passed through BSS #22 to obtain fine solid.
  • step 3 The fine solid obtained in step 2 was lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate.
  • ATENOLOL LAYER 1 Atenolol, Microcrystalline Cellulose, and Sodium Starch Glycoiate (Part 1 ) were sifted through # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution in Purified Water to obtain a wet mass.
  • step 2 The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed wiih Sodium Starch Glycoiate (Part 2),
  • step 3 The granules of step 3 were lubricated with Colloidal Anhydrous Silica and Magnesium Stearate to obtain a blend.
  • the Bi layer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 1 Carnauba wax was melled and to (his stearic acid and Isosorbide Mononitrate 80% diluted were added while stirring. 2. All melt of step 1 was solidified and milled, and passed through BSS #22 to obtain fine solid,
  • step 3 The fine solid obtained in step 2 was mixed with hypromellose to obtain a blend.
  • step 3 The blend of step 3 was lubricated with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate.
  • Atenolol, Macrocrystalline Cellulose, and Sodium Starch Glycolate (Part 1 ) were sifted through # 22 BSS and mixed to obtain a mixture
  • step 2 The mixture obtained in step 1 was granulated with Povidone solution (in Purified Water) to obtain a wet mass. 3. The wet mass obtained in step 2 was dried to obtain dried granules, the dried granules were milled and then mixed with Sodium Starch Glycolate (Part 2).
  • step 3 The granules of step 3 were lubricated with Col loidal Anhydrous Si iica and Magnesium Stearate to obtain a blend.
  • the Bilayer tablets were compressed using the blend of isosorbide mononitrate layer obtained in (A) and blend of atenolol layer obtained in (B).
  • step 2 Granulate mix of step 1 with Povidone (part 2) solution in a mixture of Isopropyl Alcohol and Purified Water.
  • step 3 After drying the wet mass obtained after step 2, mill the dried granules and lubricate with Colloidal Anhydrous Silica, Talc, and Magnesium Stearate to obtain a blend.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide, ainsi que le procédé de préparation de celle-ci. La composition assure une libération prolongée du mononitrate d'isosorbide et une libération immédiate de l'aténolol.
PCT/IB2007/052479 2006-06-26 2007-06-26 Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide WO2008001311A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1491DE2006 2006-06-26
IN1491/DEL/2006 2006-06-26

Publications (2)

Publication Number Publication Date
WO2008001311A2 true WO2008001311A2 (fr) 2008-01-03
WO2008001311A3 WO2008001311A3 (fr) 2008-05-15

Family

ID=38606877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/052479 WO2008001311A2 (fr) 2006-06-26 2007-06-26 Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide

Country Status (1)

Country Link
WO (1) WO2008001311A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058592A (zh) * 2010-12-27 2011-05-18 青岛黄海制药有限责任公司 一种阿折地平硝酸异山梨酯复方组合物
CN116139091A (zh) * 2023-03-29 2023-05-23 山东诚创蓝海医药科技有限公司 一种单硝酸异山梨酯片及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
WO1998053802A1 (fr) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Dispositif a osmose multicouches
WO2000057883A1 (fr) * 1999-03-29 2000-10-05 Bristol-Myers Squibb Company Utilisation d'inhibiteurs de la vasopeptidase pour traiter l'angine de poitrine
EP1260216A1 (fr) * 2001-05-15 2002-11-27 Peirce Management, LLC Composition pharmaceutique multicouche destinee a une administration a la fois orale et intraorale
US20030216384A1 (en) * 2002-05-16 2003-11-20 Northern Sydney Area Health Service Composition and method for treating hypertension
WO2004087175A1 (fr) * 2003-04-04 2004-10-14 Pharmacia Corporation Tablettes comprimees orales de formulations multiparticulaires a liberation prolongee
WO2005009412A1 (fr) * 2003-07-24 2005-02-03 Wockhardt Limited Compositions orales pour le traitement de maladies
US20060018934A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
WO1998053802A1 (fr) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Dispositif a osmose multicouches
WO2000057883A1 (fr) * 1999-03-29 2000-10-05 Bristol-Myers Squibb Company Utilisation d'inhibiteurs de la vasopeptidase pour traiter l'angine de poitrine
EP1260216A1 (fr) * 2001-05-15 2002-11-27 Peirce Management, LLC Composition pharmaceutique multicouche destinee a une administration a la fois orale et intraorale
US20030216384A1 (en) * 2002-05-16 2003-11-20 Northern Sydney Area Health Service Composition and method for treating hypertension
US20060018934A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
WO2004087175A1 (fr) * 2003-04-04 2004-10-14 Pharmacia Corporation Tablettes comprimees orales de formulations multiparticulaires a liberation prolongee
WO2005009412A1 (fr) * 2003-07-24 2005-02-03 Wockhardt Limited Compositions orales pour le traitement de maladies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKHRAS, F. ET AL: "Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina." LANCET, vol. 338, 26 October 1991 (1991-10-26), XP002457110 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058592A (zh) * 2010-12-27 2011-05-18 青岛黄海制药有限责任公司 一种阿折地平硝酸异山梨酯复方组合物
CN116139091A (zh) * 2023-03-29 2023-05-23 山东诚创蓝海医药科技有限公司 一种单硝酸异山梨酯片及其制备方法

Also Published As

Publication number Publication date
WO2008001311A3 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
CN105101952B (zh) 托法替布口服持续释放剂型
EP1904038B1 (fr) Composition pharmaceutiques comprimee comprenant des granules enrobes et un melange a compression directe, et procede de preparation
JP6042387B2 (ja) ヒドロコドン放出制御製剤
AU658209B2 (en) Pharmaceutical combination formulation
AU2008288106B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
US20060057202A1 (en) Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
CA2447005A1 (fr) Composition pharmaceutique a liberation controlee administree par voie orale pour therapie a dose quotidienne unique en traitement et prevention de troubles cardiaques et circulatoires
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US20100247647A1 (en) Sustained release tablets with hydromorphone
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
KR20090034372A (ko) 옥시코돈을 포함하는 과립 및 경구 붕해 정제
JPH11501948A (ja) プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形
EP2299983A1 (fr) Formulation antipsychotique atypique stabilisée
WO2009047799A1 (fr) Forme posologique pharmaceutique à usage oral unitaire solide à haute dose de mycophénolate de sodium et son procédé de fabrication
KR20080037680A (ko) 1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ｐｈ조절제를 포함하는 고체 제약학적 조성물
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
CA2678482A1 (fr) Preparation a liberation controlee contenant du cilostazol et son procede de fabrication
WO2005084636A2 (fr) Procede de preparation d'une composition pharmaceutique a liberation controlee de metoprolol
US20120003307A1 (en) Levetiracetam controlled release composition
WO2007112574A1 (fr) Composition de venlafaxine à libération prolongée
EP2698150A1 (fr) Préparation solide orale de médicament antituberculeux composé et son procédé de préparation
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
WO2013181292A1 (fr) Formulations de nitisinone
WO2008001311A2 (fr) Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide
WO2009024858A1 (fr) Forme posologique à libération contrôlée de galantamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789809

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU